After little more than a year on the job, C-Path CEO Carolyn Compton has announced plans to leave for a position with Arizona State University.
Compton will move to a new position with the ASU-based National Biomarkers Development Alliance, an organization begun last November to "create a standards-based, end-to-end pipeline for the expressed purposes of bringing rigor and predictability to biomarker development," according to an agenda of the group's December workshop.
Compton lead a discussion at the workshop series in Scottsdale.
in her stead, C-Path has named Martha Brumfield as interim CEO. Brumfield has a doctorate in organic chemistry from the University of Maryland and worked for many in the pharmaceutical industry for companies such as Pfizer.